Overview

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label Phase 1 trial to investigate the safety, PK, and pharmacodynamics of the Polθ inhibitor RP-3467 alone or in combination with the poly-ADP ribose polymerase inhibitor (PARPi) olaparib in adults with molecularly selected advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Repare Therapeutics

Treatments:

Appointments and Schedules
BID protein, human
olaparib